Combination therapy for advanced TFE3 kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a combination of three drugs (ipilimumab, sintilimab, and lenvatinib) as a first treatment for a rare and advanced type of kidney cancer called TFE3-rearranged renal cell carcinoma. The goal is to see if this combination can shrink tumors and help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of kidney cancer (TFE3-rearranged renal cell carcinoma) that has spread to other parts of the body.
- You have not received prior immunotherapy or targeted therapy for your cancer.
- You do not have active brain metastases.
- You do not have an autoimmune disease (like lupus or rheumatoid arthritis) or a history of other cancers in the last 3 years.
- You do not have uncontrolled heart disease, high blood pressure, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs together—vorolanib (a pill that targets blood vessels in tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer)—for people with advanced kidney cancer whose prior immunotherapy combination stopped working.
This study tests a combination of three treatments—an immunotherapy drug called tislelizumab, chemotherapy, and a procedure called BACE—for advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus either lenvatinib or axitinib for people with advanced clear cell kidney cancer that continued to grow after the first treatment. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This study tests a combination of two drugs (toripalimab and axitinib) as the first treatment for advanced kidney cancer that has clear cell features. The goal is to see if this drug combo can shrink tumors and possibly allow some patients to avoid or delay surgery to remove the kidney. Participation requires a tumor biopsy that shows a specific immune pattern.
This study tests a combination of three drugs—atorvastatin, axitinib, and toripalimab—to treat advanced clear-cell renal cell carcinoma (a common type of kidney cancer that has spread or cannot be surgically removed). The drugs work by targeting blood vessel growth and boosting the immune system to fight cancer cells.
Hear when a new Renal Cell Carcinoma (Kidney Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.